Avectas is a cell engineering technology company that enables drug developers to manufacture potent engineered cell therapies.
Avectas has raised €27M across 2 funding rounds from 1 investor, most recently a Series C round in Apr 2020. Based in Dublin, Ireland; founded 2010; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
| Date |
|---|
| Stage |
|---|
| Amount |
|---|
| Investors |
|---|
| 2020-04-16 | Series C | €18M | Seamus Mulligan | View deal → |
| 2019-04-01 | Other | €8.9M | Seamus Mulligan | View deal → |
